Lv1
48 积分 2024-10-22 加入
Safety considerations for cereblon-recruiting targeted protein degraders
30天前
已完结
Vav1 Haploinsufficiency in a Common Variable Immunodeficiency Patient with Defective T-Cell Function
1个月前
已完结
A Role for VAV1 in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis
1个月前
已完结
Autoreactivity by design: innate B and T lymphocytes
2个月前
已完结
Insights into autoimmunity and cancer
2个月前
已完结
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial
4个月前
已完结
Adopting GPR75 in treating obesity: unraveling the knowns and unknowns of this orphan GPCR
4个月前
已完结
Multiple sclerosis research in 2025: earlier diagnosis and halting progression
4个月前
已完结
Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials
5个月前
已完结
B cells in multiple sclerosis — from targeted depletion to immune reconstitution therapies
5个月前
已完结
皖公网安备34019202002308
